Autophagy

Deciphera Pharmaceuticals Announces Planned 2023 Corporate Milestones to Support Continued Evolution to Multi-Product Company

Retrieved on: 
Tuesday, January 3, 2023
Biotechnology, Pharmaceutical, Health, Oncology, Cancer, Gastrointestinal stromal tumor, INSIGHT, MEK, Research, Business, Pfizer, DNA, Binimetinib, Public expenditure, Tenosynovial giant cell tumor, Trial of the century, Colorectal cancer, Neoplasm, GIST, Patient, CSF1R, Cetuximab, Autophagy, TGCT, FDA, IND, Circulating tumor DNA, BRAF, KIT, International, Pharmaceutical industry, Medical device

The Company also announced plans to initiate the INSIGHT pivotal Phase 3 clinical study of QINLOCK versus sunitinib in this patient population in the second half of 2023.

Key Points: 
  • The Company also announced plans to initiate the INSIGHT pivotal Phase 3 clinical study of QINLOCK versus sunitinib in this patient population in the second half of 2023.
  • Continue European geographic expansion of QINLOCK in 2023, with planned commercial launches following conclusion of pricing and reimbursement negotiations in key European markets.
  • Nominate a new development candidate from Deciphera’s proprietary discovery engine of novel switch-control inhibitors in the first half of 2023.
  • Deciphera will host a conference call and webcast to discuss the ctDNA analysis results from the INTRIGUE Phase 3 clinical study, its planned 2023 corporate milestones and a general business update, today, January 3, 2023, at 5:00 PM ET.

First Participant Dosed in Europe as Cognition Therapeutics Expand Phase 2 Alzheimer's Disease Clinical Trial of Oral CT1812

Retrieved on: 
Thursday, December 15, 2022
Degenerative disease, Czech, Head, Intellectual property, ADAS, Clinical trial, Czech Republic, Synapse, Vance DeGeneres, Autophagy, Biogen, Antibody, Eisai, Safety, Retina, Central nervous system, Traffic barrier, Risk, DLB, Dementia, Neuron, Government budget balance, Securities & Exchange Commission of Pakistan, Biomarker, NIA, SHIMMER, Therapy, MRI, Oxidative stress, Lewy body, SHINE, COVID-19, Patient, Pharmaceutical industry, Medical device, Medical imaging, Cognition

This new mechanism of action is fundamentally distinct from and complementary with that of anti-amyloid antibody-based immunotherapy, such as lecanemab.

Key Points: 
  • This new mechanism of action is fundamentally distinct from and complementary with that of anti-amyloid antibody-based immunotherapy, such as lecanemab.
  • However, unlike antibodies, which lower brain amyloid levels, CT1812 was designed to shield neurons from these toxic proteins.”
    Results from initial trials with CT1812 provided evidence to support expansion of the clinical programs.
  • CT1812 is an oral small molecule designed to penetrate the blood-brain barrier and bind selectively to the sigma-2 (σ-2) receptor complex.
  • We are currently investigating our lead candidate CT1812 in clinical programs in Alzheimer’s disease, dementia with Lewy bodies (DLB) and dry age-related macular degeneration (dry AMD).

Casma Therapeutics Raises $46.0 M in Series C Funding

Retrieved on: 
Tuesday, November 15, 2022
Biotechnology, Pharmaceutical, Health, Oncology, Autophagy, Third Rock Ventures, MYD88, Drug development, Therapy, Casma, Neurodegeneration, IND, Disease, Inflammation, Investment, Drug discovery, Mirae Asset Financial Group, Organelle, Arrest, Protein, Patient, Pharmaceutical industry

Casma Therapeutics , Inc., a biotechnology company engaging the autophagy system to provide innovative new medicines, today announced the closing of a Series C financing round of $46.0 million.

Key Points: 
  • Casma Therapeutics , Inc., a biotechnology company engaging the autophagy system to provide innovative new medicines, today announced the closing of a Series C financing round of $46.0 million.
  • Current investors Eventide Asset Management, LLC, Schroders Capital, The Column Group, Third Rock Ventures, and other funds also participated in the financing.
  • Casma will use proceeds to advance its lead program for MYD88 mutant lymphoma through preclinical and into IND enabling studies.
  • We expect that this round of funding will accelerate development of Casmas pipeline assets, especially its degrader for MYD88 mutant tumors.

Forcefield Therapeutics presents positive preclinical data at the 2022 Scientific Sessions of American Heart Association

Retrieved on: 
Monday, November 7, 2022
American Heart Association, Protein, FTSE, Research, Science, Therapy, Heart, ICGEB, Sri Jayadeva Institute of Cardiovascular Sciences and Research, Autophagy, International Centre, Genetic engineering, Industry, Apoptosis, BMP4, Mouse, Death, Scale of Protective Factors, Adult, Knowledge, AAV, British Heart Foundation, University of Trieste, Stroke, Health, University, Phenotype, Genetics, BHF, AMI, Risk, Myocardial infarction, Disease, AHA, Patient, Heart failure, Medical device, Vaccine, Pharmaceutical industry, Biology

London UK, 7 November 2022 Forcefield Therapeutics (Forcefield) Ltd, a pioneer of best-in-class therapeutics to protect heart function by arresting the loss of cardiomyocytes following myocardial infarction, has presented positive preclinical data on three proteins identified by the FunSel platform which have potential to preserve heart function following a heart attack.

Key Points: 
  • London UK, 7 November 2022 Forcefield Therapeutics (Forcefield) Ltd, a pioneer of best-in-class therapeutics to protect heart function by arresting the loss of cardiomyocytes following myocardial infarction, has presented positive preclinical data on three proteins identified by the FunSel platform which have potential to preserve heart function following a heart attack.
  • The paper presented preclinical data outlining the mechanisms of three proteins identified by FunSel, Forcefields protein search engine.
  • It has been further developed by Mauro Giacca, Professor of Cardiovascular Sciences at Kings College London and co-founder of Forcefield Therapeutics and supported by the British Heart Foundation.
  • Forcefield Therapeutics Ltd (Forcefield Tx) is a pioneer of best-in-class therapeutics to retain heart function via protection of cardiomyocytes.

KeifeRx to Present at BioFuture 2022

Retrieved on: 
Thursday, November 3, 2022
ALS, MCAS, Hives, Georgetown University, Neurodegeneration, Patent, B cell, Autophagy, Technology, Brain, MBBS, Amyotrophic lateral sclerosis, Alzheimer's disease, TKI, Vaccine

CEO Chris Hoyt stated, "We are looking forward to presenting our portfolio of optimized TKIs designed to treat neurodegenerative and immune diseases at BioFuture 2022.

Key Points: 
  • CEO Chris Hoyt stated, "We are looking forward to presenting our portfolio of optimized TKIs designed to treat neurodegenerative and immune diseases at BioFuture 2022.
  • KeifeRx's diverse pipeline of early- and late-stage products leverages mechanisms of action inherent to TKIs which thus far have been underexplored.
  • KeifeRx has an exclusive license of the intellectual property from Georgetown University.
  • For more information on KeifeRx, please visit https://www.keiferx.com .

Hayashibara Brings Back "Trehalose Symposium" to Reveal Its Game-changing Versatilities in Human Biochemistry

Retrieved on: 
Tuesday, October 4, 2022
Research, Trehalose, Autophagy, Nobel Prize, Ice, Cell, Society, Carbohydrate, Pharmaceutical industry

This highly specialized academic event returned to Tokyo after a three-year hiatus, engaging 231 attendees in person and online from various fields.

Key Points: 
  • This highly specialized academic event returned to Tokyo after a three-year hiatus, engaging 231 attendees in person and online from various fields.
  • Researchers from home and abroad presented their basic and applied research results on trehalose.
  • Hayashibara is dedicated to continuing the Trehalose Symposium, providing a community for researchers worldwide to present their findings and obtain beneficial information by interacting with peers.
  • Through its commitment to basic research for trehalose, Hayashibara envisions the Trehalose Symposium to contribute to building a sustainable society.

Hayashibara Brings Back "Trehalose Symposium" to Reveal Its Game-changing Versatilities in Human Biochemistry

Retrieved on: 
Tuesday, October 4, 2022
Research, Trehalose, Autophagy, Nobel Prize, Ice, Cell, Society, Carbohydrate, Pharmaceutical industry

This highly specialized academic event returned to Tokyo after a three-year hiatus, engaging 231 attendees in person and online from various fields.

Key Points: 
  • This highly specialized academic event returned to Tokyo after a three-year hiatus, engaging 231 attendees in person and online from various fields.
  • Researchers from home and abroad presented their basic and applied research results on trehalose.
  • Hayashibara is dedicated to continuing the Trehalose Symposium, providing a community for researchers worldwide to present their findings and obtain beneficial information by interacting with peers.
  • Through its commitment to basic research for trehalose, Hayashibara envisions the Trehalose Symposium to contribute to building a sustainable society.

 Rocket Pharmaceuticals Announces Positive Updates from Phase 1 Clinical Trial for RP-A501 in Danon Disease at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022

Retrieved on: 
Friday, September 30, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Adult, LV, Safety, Heart Failure Society of America, Pyruvate kinase deficiency, Blood, Cardiac muscle, PKD, Patient, Bone marrow failure, Gene expression, Genetic disorder, NASDAQ, Disease, Death, Risk, Fanconi anemia, COVID-19, Prevalence, AAV, Degenerative disease, Lists of diseases, Heart failure, Glycogen, LVV, Medication, Toxic leukoencephalopathy, SEC, Diastole, Troponin, Freedom, Immunohistochemistry, II, Investor, FDA, Ventricular hypertrophy, Adolescence, Data, BNP, Tissue, Marketing, Blunt cardiac injury, Autophagy, FA, Private Securities Litigation Reform Act, Autophagosome, Quality of life, Male, Heart transplantation, New York Heart Association Functional Classification, KCCQ, Biopsy, Webcast, Pharmaceutical industry, Dentistry, Medical device, Medicine, Vaccine, Danon disease, NYHA

Further, efficacy data from the pediatric patients are following similar or more favorable positive trends as in the adults at a similar timeframe.

Key Points: 
  • Further, efficacy data from the pediatric patients are following similar or more favorable positive trends as in the adults at a similar timeframe.
  • RP-A501 is an investigational gene therapy product being developed for Danon Disease and the first potential gene therapy for monogenic heart failure.
  • Rockets first clinical program using adeno-associated virus (AAV)-based gene therapy is for Danon Disease, a devastating, pediatric heart failure condition.
  • Although Rocket believes that the expectations reflected in the forward-looking statements are reasonable, Rocket cannot guarantee such outcomes.

Greg Lindberg Creates YouTube Videos To Empower Prisoners and Others Facing Life's Troubles, Based on His Book 633 Days Inside

Retrieved on: 
Wednesday, September 28, 2022
YouTube, Health, Hormesis, Memory, Muscle, Autophagy, Policy, Brain, United States Court of Appeals for the Fourth Circuit, The, Fifth Amendment, Name, Life, Survival, Robert Stroud, Sixth Amendment, Southwestern Advantage, Leadership, BDNF, Neurogenesis, Birdman, Bird, Science, Method, Collection, Global Growth, Appeal, Skin, Amazon, Education, Fasting, Pharmaceutical industry, Medicine, Yale University

His incarceration story of survival and triumph is shared in the new book, 633 Days Inside: Lessons on Life and Leadership .

Key Points: 
  • His incarceration story of survival and triumph is shared in the new book, 633 Days Inside: Lessons on Life and Leadership .
  • Now, in an effort to help anyone concerned with overcoming the soul-wrenching struggles of prison life, Lindberg is offering a series of videos on YouTube.
  • With his new YouTube videos, Greg Lindberg wants to help "cellies" everywhere, and people in general, to have better health and a better life.
  • Customers can find the print and ebook of 633 Days Inside on Amazon and other major outlets.

Coave Therapeutics to Collaborate with World-Renowned Institute of Neurodegenerative Diseases of Bordeaux to Develop Gene Therapy Programs Targeting Protein Degradation in Neurodegenerative Disorders

Retrieved on: 
Wednesday, September 14, 2022
Institute, Degenerative disease, Central nervous system, Neurodegeneration, University of Bordeaux 1, Autophagy, CNRS, AAV, MD, MSA, French National Centre for Scientific Research, Phenotype, Coronavirus Scientific Advisory Board (Turkey), Scientific method, IND, Parkinson's disease, Re Recher's Will Trusts, Partnership, National Centre for Disease Control, Therapy, INSERM, EB, CEO, TFEB, SAB, Multiple system atrophy, CNS, Eye, University, PD, IMN, Pharmaceutical industry, Vaccine, Medical device, Wood drying, Genetics, Idinvest Partners, Medicine

Overexpression of TFEB via gene therapy demonstrates potential to reduce and prevent the accumulation of toxic protein aggregates1 and to consequently prevent neurodegeneration.

Key Points: 
  • Overexpression of TFEB via gene therapy demonstrates potential to reduce and prevent the accumulation of toxic protein aggregates1 and to consequently prevent neurodegeneration.
  • We look forward to leveraging our collective strengths to best develop gene therapy programs for neurodegenerative diseases with the potential to improve patient outcomes."
  • "We are delighted to be collaborating with IMN to develop coAAVs carrying TFEB and explore these gene therapy constructs for the treatment of neurodegenerative diseases.
  • Coave Therapeutics is a clinical-stage biotechnology company focused on developing life-changing gene therapies for CNS (Central Nervous System) and eye diseases.